The press release goes on to say
Lovell Drugs will, in partnership with Maricann, implement a medical cannabis education and access program for its pharmacists and allied community physicians that facilitates the counselling and fulfillment of medical cannabis to its patients.
Maricann will fulfill prescriptions directly to Lovell Drugs’ patients through the existing Access to Cannabis for Medicinal Purposes Regulations.
Lovell Drugs has already commenced distribution of Maricann cannabis products to its patients, with the first prescription registered and fulfilled on December 1st, 2017.
The term of the agreement is four years, with an option to extend another three years if the parties mutually agree. Pursuant to the terms of the agreement Lovell Drugs will receive a percentage of Maricann product sale revenue generated from patients acquired and serviced from Lovell Drugs’ retail pharmacies. As part of the development of medical cannabis content Maricann has agreed to provide funding of up to $15,000 for initiatives to support continuing education for Lovell Drugs personnel and their patients.
